BLACK FRIDAY SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim→
logo
← Back to IPO overview
Sahajanand Medical Technologies logo

Mainboard IPO

Sahajanand Medical Technologies IPO

ListedBSE, NSE

Prices in INR · Times in IST

GMP updated: 23 Oct 2026, 08:24 AM IST

Price band
₹327 – ₹344
Application estimate
₹14,7921 lot(s) · 43 sh
GMP · unofficial
₹17 (+4.94%)
Est. listing price
₹361Issue price + GMP
Issue size
₹475.48 Cr
Total subscription
14.2×

GMP trend & intraday history

23 Oct 2026
₹17+4.94%₹0 vs previous
Est. profit (1 lot · 43 sh)₹731
Issue price + GMP₹361
43291511 Oct 2026: ₹4012 Oct 2026: ₹3513 Oct 2026: ₹4114 Oct 2026: ₹4115 Oct 2026: ₹4316 Oct 2026: ₹3517 Oct 2026: ₹1518 Oct 2026: ₹2819 Oct 2026: ₹2420 Oct 2026: ₹2421 Oct 2026: ₹2122 Oct 2026: ₹1723 Oct 2026: ₹1711 Oct 202623 Oct 2026

Hover or tap on the chart to inspect a reading. Dates use calendar spacing; large gaps are not connected.

High in this view
₹43 (₹1,849)
Low in this view
₹15 (₹645)
Reference issue price
₹344
Readings in this view
13
Subject to sauda
500 / 7000
GMP source readings
ReadingGMPPremium %Issue price + GMPEst. profit (1 lot · 43 sh)Subject to sauda
11 Oct 2026₹40—₹384₹1,7200
12 Oct 2026₹35(+10.17%)₹379₹1,5051300 / 18200
13 Oct 2026₹41(+11.92%)₹385₹1,7631100 / 15400
14 Oct 2026₹41(+11.92%)₹385₹1,7631200 / 16800
15 Oct 2026₹43(+12.5%)₹387₹1,8491300 / 18200
16 Oct 2026₹35(+10.17%)₹379₹1,5051400 / 19600
17 Oct 2026₹15(+4.36%)₹359₹6451100 / 15400
18 Oct 2026₹28(+8.14%)₹372₹1,204500 / 7000
19 Oct 2026₹24(+6.98%)₹368₹1,032500 / 7000
20 Oct 2026₹24(+6.98%)₹368₹1,032500 / 7000
21 Oct 2026₹21(+6.1%)₹365₹903800 / 11200
22 Oct 2026₹17(+4.94%)₹361₹731500 / 7000
23 Oct 2026₹17(+4.94%)₹361₹731500 / 7000

Issue at a glance

Issue Size₹475.48 Cr
Price Band₹327 – ₹344
Final Issue Price₹344
Face Value₹1
Lot Size43 Shares
Employee Discount—
Issue TypeOFS only
Listing ExchangesBSE, NSE
NSE SymbolSMT.NS
BSE Scrip Code8043

IPO timetable & schedule

Completed IPO lifecycleListed · 23 Oct 2026
IPO Open Date
Bidding opens
IPO Close Date
Bidding closes
Basis of Allotment
Allotment finalisation
Initiation of Refunds
Unallotted funds unblocked
Credit of Shares to Demat
Shares credited to demat
Tentative Listing Date
Exchange listing (BSE / NSE)

Subscription by investor category

Source updated: 23 Oct 2026, 06:30 PM IST

Overall Demand: 14.2×
QIB (Institutional)34.7×
Bid: 94179804Offered: 2714423
NII / HNI14.64×
Bid: 29808460Offered: 2035818
Retail (Individual)3.03×
Bid: 14391713Offered: 4750241
Employee0.37×
Bid: 92794Offered: 250000
Shareholder0×
Bid: 0Offered: —
Investor categoryTimes subscribedShares offeredShares bidApplicationsDemand (₹ crore)
Qualified Institutional Buyers (QIB)34.7×27144239417980441₹3239.79 Cr
↳ Foreign Institutional Investors——32379301—₹1113.85 Cr
↳ Domestic Financial Institutions——29126308—₹1001.94 Cr
↳ Mutual Funds——17203354—₹591.8 Cr
↳ Others——15470841—₹532.2 Cr
Non-Institutional Investors (NII)14.64×20358182980846019653₹1025.41 Cr
↳ bNII — bids above ₹10 Lakh16.37×1357212222127257391₹764.12 Cr
↳ bNII — Corporates——471022—₹16.2 Cr
↳ bNII — Individuals——20762894—₹714.24 Cr
↳ bNII — Others——978809—₹33.67 Cr
↳ sNII — bids ₹2 Lakh to ₹10 Lakh11.19×678606759573512262₹261.29 Cr
↳ sNII — Corporates——43946—₹1.51 Cr
↳ sNII — Individuals——7309011—₹251.43 Cr
↳ sNII — Others——242778—₹8.35 Cr
Retail Individual Investors (RII)3.03×475024114391713293875₹495.07 Cr
↳ Cut-off price bids——12366585—₹425.41 Cr
↳ Price bids——2025128—₹69.66 Cr
Employee0.37×25000092794147₹3.19 Cr
↳ Cut-off price bids——72541—₹2.5 Cr
↳ Price bids——20253—₹0.7 Cr
Shareholder0×—0—₹0 Cr
↳ Cut-off price bids—————
↳ Price bids—————
Total14.2×9750482138472771313716₹4763.46 Cr

Mainboard figures are consolidated. NSE and BSE demand is not added together. Rupee demand is calculated from bid shares and the cap price; it is not an exchange-published amount. Application source: boa.

QIB funding cost illustration

Arithmetic for a fully funded institutional bid over 7 days; not a recommendation or a retail return estimate.

Days
7
Interest Rate
Not published
Cost Per Share
11936.8

Day-wise subscription history

One snapshot near each bidding day’s close. This is not a continuous intraday series.

DayDateTime (IST)QIBNIIRetailEmployeeShareholderTotal
115 Oct 202619:30:300.37×0.2×0.4×0.08×0×0.34×
216 Oct 202619:30:451.12×0.51×0.82×0.14×0×0.82×
319 Oct 202619:30:2834.7×14.64×3.03×0.37×0×14.2×

Plan your application

APPLICATION REFERENCE
Listed 23 Oct 2026
Minimum application estimate₹14,7921 lot · At upper band

Estimate uses the published lot size and upper price band. Confirm your category and the offer terms before applying.

43 shares × ₹344₹14,792

One lot: ₹14,792 · Allocation is not guaranteed. Broker cut-off times may differ.

Source-published application tiers
Source categoryLotsSharesAmount
Retail (Min)143₹14,792
Retail (Max)13559₹1,92,296
S-HNI (Min)14602₹2,07,088
B-HNI (Min)682924₹10,05,856
Before you place an IPO application
  1. Read the issue. Check the offer document, business risks, price band and your application category.
  2. Apply through your broker or bank. Use your existing broker’s IPO section or your bank’s ASBA facility. This page does not submit a bid.
  3. Check the payment step. If using UPI, confirm the mandate in your UPI app and check that the funds are blocked. A saved bid alone is not confirmation.
  4. Track what happens next. Keep your application number. Use the registrar’s official page for allotment and the published timeline for refunds, demat credit and listing.

GMP return scenario

What could this amount look like?

GMP-based scenario · Not a forecast

Application amount₹14,79243 shares
GMP-based gain / loss₹731+4.94%
Illustrative value₹15,523Before fees and taxes

Assumes all requested shares are allotted and listing equals issue price + GMP. Actual allotment, listing price, fees and taxes can change the result.

Your IPO progress

Keep your own record of this IPO. Statuses are entered by you, not verified with a broker or registrar. Saved on this browser for your signed-in account; not synced across devices.

IPO reservation & shares offered

Investor CategoryAllocation / Reservation
QIB67,86,058 shares (50.00% of the Offer)
NII20,35,817 shares (15.00% of the Offer)
Retail47,50,241 shares (35.00% of the Offer)
Employee2,50,000 shares (1.81% of the Offer)

Shares offered by category

QIB Shares Offered2714423
NII (HNI) Shares Offered2035818
Retail Shares Offered4750241

Category-wise allocation percentages follow SEBI ICDR norms as stated in the offer document.

Promoter holding & ownership

Pre-Issue Holding40.82%
Post-Issue Holding36.2%

Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen and Shree Hari Trust

Promoters hold 40.82% before the issue and will hold 36.2% after it.

Anchor investors & allocations

Anchor entities
10
Total allocation (₹ crore)
140.06
Mutual fund allottees
7
Official allocation document
Anchor document: not published

Investor allocations

InvestorFund houseSharesAmount (₹ crore)% of anchor book% of issue
NIPPON INDIA SMALL CAP FUNDNIPPON INDIA MUTUAL FUND114509039.3928.12%8.28%
DSP HEALTHCARE FUNDDSP MUTUAL FUND59099220.3314.51%4.28%
WHITEOAK CAPITAL FLEXI CAP FUNDWHITEOAK CAPITAL MUTUAL FUND1843416.344.53%1.33%
WHITEOAK CAPITAL MULTI ASSET ALLOCATION FUNDWHITEOAK CAPITAL MUTUAL FUND8720432.14%0.63%
WHITEOAK CAPITAL PHARMA & HEALTHCARE FUNDWHITEOAK CAPITAL MUTUAL FUND14534053.57%1.05%
INVESCO INDIA PHARMA & HEALTHCARE FUNDINVESCO MUTUAL FUND4360631510.71%3.15%
UTI HEALTHCARE FUNDUTI MUTUAL FUND4360631510.71%3.15%
ALLIANZ GLOBAL INVESTORS FUND-ALLIANZ INDIA EQUITYALLIANZ4360631510.71%3.15%
TATA AIA LIFE INSURANCE CO.LTD.-WHOLE LIFE AGGRESSIVE GROWTH FUND-ULIF 010 04/01/07 WLA 110TATA AIA LIFE INSURANCE290723107.14%2.1%
NATIXIS INTERNATIONAL FUNDS (LUX) I-LOOMIS SAYLES GLOBAL EMERGING MARKETS EQUITY FUNDNATIXIS319755117.85%2.31%

By fund house

Fund houseAnchorsAmount (₹ crore)
NIPPON INDIA MUTUAL FUND139.39
DSP MUTUAL FUND120.33
INVESCO MUTUAL FUND115
UTI MUTUAL FUND115
ALLIANZ115
WHITEOAK CAPITAL MUTUAL FUND314.34
NATIXIS111
TATA AIA LIFE INSURANCE110

Financials & valuation

Figures in Rs. Crore · Changes compare matching annual period-end dates only.

Profit After Tax
15.09Latest: 30 Jun 2026Prior (31 Mar 2026): 69.08 · YoY unavailable
EBITDA
48.58Latest: 30 Jun 2026Prior (31 Mar 2026): 170.66 · YoY unavailable
Total Borrowing
320.63Latest: 30 Jun 2026Prior (31 Mar 2026): 269.53 · YoY unavailable
Financial performance
Assets · Rs. Crore₹1,309↑+2.6%
Positive
970.58
31 Mar '24
1,094.9
31 Mar '25
1,276.43
31 Mar '26
1,309
30 Jun '26

Rs. Crore

Metric30 Jun 202631 Mar 202631 Mar 202531 Mar 2024
Assets1,309.001,276.431,094.90970.58
Total Income354.331,218.731,035.96908.59
Profit After Tax15.0969.0825.15-7.35
EBITDA48.58170.66128.02110.05
NET Worth631.72616.05545.23526.30
Reserves and Surplus706.86692.48580.71556.57
Total Borrowing320.63269.53224.96175.27

Key valuation & financial KPIs

P/E Ratio
57.91
EPS (₹)
5.94
RoE
2.07%
RoCE
3.16%
RoNW
2.31%
PAT Margin
4.29%
EBITDA Margin
13.81%
Debt / Equity
0.33
NAV (₹)
64.35

What does the company do?

Sahajanand Medical Technologies Ltd. was founded in 2001 by Dhirajlal Kotadia. It is a medical device company focused on Class III and Class C/D devices, mainly for vascular and structural heart intervention. It was the first company in the world to get CE certification for a drug-eluting stent with a biodegradable polymer, called Infinnium. The products fall in three groups. Vascular intervention covers coronary stents and balloons. Structural heart covers TAVI and occluders. Other products include renal stents, peripheral drug-coated balloons and some trading products. The company has two R&D centres, one in India and one in Thailand, with 102 professionals. It holds 102 granted patents globally and has 71 pending applications. Key brands are Supraflex Cruz, Hydra (TAVI) and Cocoon (occluders), backed by 72 clinical studies and sold in over 76 countries. It sells directly in Germany, Spain, France and the UK, uses a hybrid model in India and distributors in markets such as Italy. As of 31 March 2025 it had 1,458 full-time staff, 24 consultants and 818 contract personnel.

More about the business

Sahajanand Medical Technologies makes Class III heart devices such as drug-eluting stents, TAVI valves and occluders. Total income was Rs 1,218.73 crore in FY2026 and restated profit after tax was Rs 69.08 crore.

Where will the money go?

Use of proceedsAmount (₹ crore)
Offer for sale by the selling shareholders. The company receives no proceeds from the offer—

Strengths & risks

Business strengths

  • Total income grew from Rs 908.59 crore in FY2024 to Rs 1,035.96 crore in FY2025 and Rs 1,218.73 crore in FY2026.
  • Profit after tax moved from a loss of Rs 7.35 crore in FY2024 to Rs 25.15 crore in FY2025 and Rs 69.08 crore in FY2026.
  • EBITDA rose from Rs 110.05 crore in FY2024 to Rs 170.66 crore in FY2026, with an EBITDA margin of 13.81%.
  • Net worth rose from Rs 526.30 crore in FY2024 to Rs 616.05 crore in FY2026, and Rs 631.72 crore on 30 June 2026.
  • The company holds 102 granted patents and its products are backed by 72 clinical studies.
  • Products are sold in over 76 countries, with direct operations in Germany, Spain, France and the UK.

Risks to understand

  • The whole issue is an offer for sale of Rs 475.48 crore. The company receives no money from it, so none of the proceeds fund growth or reduce borrowing.
  • At the upper band of Rs 344 the issue is priced at 57.91 times post issue EPS of Rs 5.94. One lot is 43 shares, about Rs 14,792 at the upper band.
  • RoNW is 2.31% and RoCE is 3.16%, which are low for the size of the business, and FY2024 was a loss year.
  • Total borrowing rose from Rs 175.27 crore in FY2024 to Rs 269.53 crore in FY2026 and Rs 320.63 crore on 30 June 2026.
  • Promoter holding falls from 40.82% before the issue to 36.2% after it.
  • The business depends on regulated Class III devices, so product approvals, clinical results and tenders can affect revenue.
  • Sales are spread over many countries, so currency moves and local rules can affect results.

Source-provided company information. Read the RHP for the complete risk factors; these points are not a recommendation.

Listing performance

Listing price₹371.15
Listing day gain+7.89%
Current market price₹539.05
Current gain vs IPO+56.7%

Actual listing figures appear after listing. Current gain is source-adjusted for corporate actions. CMP is a source snapshot, not a streaming quote.

Official documents, registrar & contacts

Offer documents

Red Herring Prospectus (RHP)
Draft Prospectus (DRHP)
Read DRHP: not published
Anchor Allocation
Read Anchor Doc: not published
Basis of Allotment
Registrar & Allotment

MUFG Intime India Private Limited

Phone: 022-49186000

Email: sahajanandmedical.ipo@in.mpms.mufg.com

Allotment date: 21 Oct 2026

Book Running Lead Managers
  • •HSBC Securities & Capital Markets (India) Pvt. Ltd.
  • •Nuvama Wealth Management Ltd.
  • •Motilal Oswal Investment Advisors
  • •Avendus Capital
Company Registered Office

Sahajanand Estate, Wakharia Wadi, NR. Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat, 395004

Phone: 022 49564000

Email: investors.grievance@smt.in

Continue your IPO research

Explore more IPO companies

Related by issue type, with active issues first. These are research links, not investment recommendations.

IPO data by StockeZee · Prices in INR · Times in IST

GMP is an unofficial, unregulated market signal. Issue price + GMP is an arithmetic reference, not a listing forecast or assured return. Subscription does not guarantee allotment. Read the offer documents and company risks before investing.